Advertisement

Malignant Melanoma

Keywords

Sentinel Node Sentinel Node Biopsy Cutaneous Melanoma Gamma Probe Lymphatic Mapping 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R, Berman CG, Jared K, Messina J, Lyman G, Glass F, Fenske N, Reintgen DS (1996) Intraoperative radio-lymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 223:217–224CrossRefPubMedGoogle Scholar
  2. Alex JC, Krag DN (1993) Gamma-probe guided localization of lymph-nodes. Surg Oncol 2:137–143PubMedGoogle Scholar
  3. Alex JC, Krag DN (1996) The gamma-probe-guided resection of radiolabeled primary lymph-nodes. Surg Oncol Clin North Am 5:33–41Google Scholar
  4. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN (1993) Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2:203–208CrossRefGoogle Scholar
  5. Alex JC, Krag DN, Halow SP, Meijer S, Loggie BW, Kuhn J, Gadd M, Weaver DL (1998) Localization of regional lymph-nodes in melanomas of head and neck (see comments). Arch Otolaryngol Head Neck Surg 124:135–140PubMedGoogle Scholar
  6. ASCO (American Society of Clinical Oncology) (2000) Proceedings of ASCO Meeting, 2000, abstract 2257 (Arance et al)Google Scholar
  7. ASCO (American Society of Clinical Oncology) (2000) Proceedings of ASCO Meeting, 2000, abstract 2248 (Kamanabrou et al)Google Scholar
  8. ASCO (American Society of Clinical Oncology) (2000) Proceedings of ASCO Meeting, 2000, abstract 2244 (Kersten et al)Google Scholar
  9. ASCO (American Society of Clinical Oncology) (2000) Proceedings of ASCO Meeting, 2000, abstract 2251 (Tres et al)Google Scholar
  10. Bachter D, Balda BR, Vogt H, Büchels H (1998) Primary therapy of malignant melanomas: sentinel lymphadenectomy. Int J Dermatol 37:278–282CrossRefPubMedGoogle Scholar
  11. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA (1979) Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 43:883–888PubMedGoogle Scholar
  12. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA (1979) A multifocal analysis of melanoma II. Prognostic factors in patients with stage I (localized) melanoma surgery. Cancer 86:343–351Google Scholar
  13. Balch CM, Soong S-J, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA (1982) A comparison of prognostic factors and surgical results in 1.786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 196:677–684PubMedGoogle Scholar
  14. Balch CM, Cascinelli N, Milton GW, Simm FH (1988) Elective Lymphknotendissektion: Pro und Contra. In: Balch CM, Milton GW (eds) Hautmelanome: Behandlungswege, Therapie und weltweite Ergebnisse. Springer, Berlin Heidelberg New YorkGoogle Scholar
  15. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thomson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMedGoogle Scholar
  16. Bartolomei M, Testori A, Chinol M, Gennari R, De-Cicco C, Leonardi L, Zoboli S, Paganelli G (1998) Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids. Eur J Nucl Med 25:1489–1494PubMedGoogle Scholar
  17. Bedrosian I, Scheff AM, Mick R, Callans LS, Bucky LP, Spitz FR, Helsabeck C, Elder DE, Alavi A, Fraker DF, Czerniecki BJ (1999) Technetium-99m human serum albumin: an effective radiotracer for identifying sentinel lymph-nodes in melanoma. J Nucl Med 40:1143–1148PubMedGoogle Scholar
  18. Ben Izhak O, Levy R, Weill S, Groisman G, Cohen H, Stajerman S, Misselevich I, Nitecky S, Eidelman S, Kerner H (1997) Anorectal malignant melanoma. A clinicopathologic study, including immunohistochemistry and DNA-flow cytometry. Cancer 79:18–25CrossRefPubMedGoogle Scholar
  19. Bostick P, Essner R, Glass E, Kelly M, Sarantou T, Foshag LJ, Qi K, Morton DL (1999) Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 134:43–49CrossRefPubMedGoogle Scholar
  20. Bowsher WG, Taylor BA, Hughes LA (1986) Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 73:906–908PubMedGoogle Scholar
  21. Breslow A (1970) Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908PubMedGoogle Scholar
  22. Büchels HK, Bachter D, Vogt H (1998) Sentinel-Lymphadenektomie beim malignen Melanom [Sentinel lymphadenectomy in malignant melanoma]. Chirurg 69:701–707CrossRefPubMedGoogle Scholar
  23. Büchels HK, Vogt H, Starz H, Bachter D (2000) Melanoma. Results with “sentinel node” sampling. Zentralbl Chir 125(10):810–812CrossRefPubMedGoogle Scholar
  24. Cafiero F, Peressini A, Gipponi M, Rainero ML, Villa G, Sertoli MR, Bertoglio S, Moresco L (1998) Sentinel node biopsy in patients with cutaneous melanoma. Semin Surg Oncol 15:284–286CrossRefPubMedGoogle Scholar
  25. Caldwell CD, Spiro RH (1988) The role of parotidectomy in the treatment of cutaneous head and neck melanoma. Am J Surg 156:318–322PubMedGoogle Scholar
  26. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB, Edwards MJ, McMasters KM (Sunbelt Melanoma Trial Group) (1992) Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 184(6):520–524CrossRefGoogle Scholar
  27. Clary BM, Mann B, Brady MS, Lewis JJ, Coit DG (2001) Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 8(4):328–337PubMedGoogle Scholar
  28. Coit DG (1993) Role of surgery for metastatic malignant melanoma. Semin Surg Oncol 9:239–245PubMedGoogle Scholar
  29. Davison SP, Clifton MS, Kauffman L, Minasian L (2001) Sentinel node biopsy for the detection of head and neck melanoma: a review. Ann Plast Surg 47(2):206–211CrossRefPubMedGoogle Scholar
  30. Dräger E, Winter H, Breuninger H, Stadler R, Sterry W (2000) Berliner Konsensuskonferenz: Sentinel Lymph Node Biopsy beim malignen Melanom der Haut, 26 February 1999, University Hospital Dermatology Department, Charité, Berlin: Report of the meeting and consensus paper. H+G: Z Hautkrankh 2(75):113–188Google Scholar
  31. Dräger E, Munz EL, Sterry W, Winter H (2001) Sentinel lymph node biopsy in malignant melanoma of the skin. In: Munz DL (ed) International forum of nuclear medicine: the sentinel lymph node concept in oncology. Zuckschwerdt, Munich, pp 83–96Google Scholar
  32. Drepper H, Köhler CO, Bastian B, Breuninger H, Brocker EB, Gohl J, Groth W, Hermanek P, Hohenberger W, Lippold A et al (1994a) Benefit of elective node dissection in subgroups of melanoma patients results of a multicenter study in 3616 patients. Cancer 72:741–749Google Scholar
  33. Drepper H, Köhler CO, Bastian B, Breuninger H, Brocker EB, Gohl J, Groth W, Hermanek P, Hohenberger W, Kölmel K (1994b) Prognostic advantage for defined risk groups by lymphocyte dissection. Long term study of 3616 melanoma patients. Hautarzt 45(9):615–622CrossRefPubMedGoogle Scholar
  34. Dresel S, Weiss M, Heckmann M, Rossmüller B, Konz B, Tatsch K, Hahn K (1998) Diagnosis of sentinel lymph node in malignant melanoma: preoperative lymphoscintigraphy and intraoperative gamma probe guidance. Nuklearmedizin 37:177–182PubMedGoogle Scholar
  35. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sorensen SS, Drzewiecki KT, Hojgaard L, Friberg L (2000) Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27:70–75PubMedGoogle Scholar
  36. Eton O (2000) Proceedings of American Society of Clinical Oncology (ASCO) Meeting, 2000. Abstract 2174Google Scholar
  37. Eton O, East M, Legha SS, Bedikian A, Buzaid AC, Papadopoulos N, Hodges C, Gianni M, Carrasco CH, Benjamin RS (1999) Pilot study of intra-arterial cisplatin and intravenous vinblastine and dicarbazine ion patients with melanoma in transit metastases. Melanoma Res 9(5): 483–489PubMedGoogle Scholar
  38. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemofherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(10):2411–2414CrossRefPubMedGoogle Scholar
  39. Fearfield LA, Rowe A, Francis N, Fisher C, Gore ME, Bunker CB (2001) Clinicopathological features of relapsing very thin melanomas. Clin Exp Dermatol 26:686–695CrossRefPubMedGoogle Scholar
  40. Fliquete Peris MV, Gimenez Climent J, Vazquez Forner C, Fuster Diana C, Martinez Carsi C, Campos Manez J, Vazquez Albaladejo C (2000) Lympho-gammagraphy and study of sentinel node in cutaneous melanoma. Rev Esp Med Nucl 19(5):331–336PubMedGoogle Scholar
  41. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch DM, Ross MI (1988) Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253–2260Google Scholar
  42. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI (1999) Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 12 stage I or II melanoma patients. J Clin Oncol 17:975–983Google Scholar
  43. Gogel BM, Kuhn JA, Ferry KM, Fisher TL, Preskitt JT, O'Brien JC, Lieberman ZH, Stephens JS, Krag DN (1998) Sentinel lymph node biopsy for melanoma. Am J Surg 176:544–547CrossRefPubMedGoogle Scholar
  44. Goldfarb LR, Alazraki NP, Eshima D, Eshima LA, Herda SC, Halkar RK (1998) Lymphoscintigraphic identification of sentinel lymph-nodes: clinical evaluation of 0.22-micron filtration of Tc-99m sulfur colloid. Radiology 208:505–509PubMedGoogle Scholar
  45. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cuppisol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang O, Bonerandi JJ for the French Cooperative Group on Melanoma (1998) Randomised trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905–1910CrossRefPubMedGoogle Scholar
  46. Hazard LJ, Sauseoyes RD (2002) Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiotoxicity. Int J Radiat Oncol Biol Phys 1, 52(3):796–800CrossRefGoogle Scholar
  47. Heenan PJ, Elder DE, Sobin LH (1974, 1996) Histological typing of skin tumors. Springer, Berlin Heidelberg New YorkGoogle Scholar
  48. Helmke BM, Deichmann M, Otto HF (2001) Anorectal melanomas do not harbour the Kaposi sarcoma-associated human herpesvirus type 8 DNA. J Med Virol 64(19):47–50CrossRefPubMedGoogle Scholar
  49. Hochwald SN, Coit DG (1998) Role of elective lymph node dissection in melanoma. Semin Surg Oncol 14:276–282CrossRefPubMedGoogle Scholar
  50. Holder WD, White RL, Zuger JH, Easton EJ, Greene FL (1998) Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227:764–769CrossRefPubMedGoogle Scholar
  51. Jacobs IA, Chevinsky AH, Swayne LC, Magidson JG, Britto EJ, Smith TJ (2001) Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: reliability of the procedure and analysis of failures after long-term follow-up. J Surg Oncol 77(3):157–164CrossRefPubMedGoogle Scholar
  52. Johansson M, Pisa EK, Tormanen V, Astrand K, Kagedal B (2000) Quantitative analysis of tyrosine transcripts in blood. Clin Chem 46(7):921–927PubMedGoogle Scholar
  53. Kapteijn BAE, Baidjnath Panday RKL, Liem IH (1995) Lymphoscintigraphy and intraoperative gamma probe detection of the first draining lymph node in clinically localized melanoma. J Nucl Med 36:222Google Scholar
  54. Kapteijn BAE, Nieweg OE, Valdes Olmos RA, Liem IH, Panday RKLB, Hoefnagel CA, Kroon BBR (1996) Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma. J Nucl Med 37:972–975PubMedGoogle Scholar
  55. Kapteijn BAE, Nieweg OE, Liem I, Mooi WJ, Balm AJ, Müller SH, Peterse JL, Valdes Olmos RA, Hoefnagel CA, Kroon BB (1997) Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 4:156–160PubMedGoogle Scholar
  56. Kapteijn BA, Nieweg OE, Müller SH, Liem IH, Hoefnagel CA, Rutgers EJ, Kroon BB (1997) Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med 38:362–366PubMedGoogle Scholar
  57. Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stolz W, Gerdes J (1989) Tumor cell growth fractions in human malignant melanomas and the correlation to histopathological tumor grading. Am J Pathol 134:1063–1068PubMedGoogle Scholar
  58. Kirkwood JM (1999) Proceedings of the American Society of Clinical Oncology (ASCO) Meeting, 1999. Abstract 2072Google Scholar
  59. Kirkwood JM, Straderman MH, Ernsthoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alpha 2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group, trial EAST 1684 (rapid publication). J Clin Oncol 14:7–17PubMedGoogle Scholar
  60. Kirkwood JM, Resnick GD, Cole BF (1997) Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 24[1 Suppl4]:S16–23Google Scholar
  61. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M (2002a) Interferon alpha-2a for melanoma metastases. Lancet 359:978–979CrossRefPubMedGoogle Scholar
  62. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donelly S, Strover L (2002b) Mechanisms and management of toxicities associated with high-dose interferon alpha-2b therapy. J Clin Oncol 20(17):3703–3718PubMedGoogle Scholar
  63. Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernsthoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mescari R (2002c) Immunomodulatory effects of high-dose interferon alpha 2b in patients with high-risk resected melanoma: the E26690 laboratory corollary of intergroup adjuvant trial E 1690. Cancer 95(5):1101–1112CrossRefPubMedGoogle Scholar
  64. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Miksche M (1990) Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. J Invest Dermatol 95[6 Suppl]:193S–197SCrossRefPubMedGoogle Scholar
  65. Korabiowska M, Brinck U, Hoenig JF, Bartkowski SB, Mirecka J, Schauer A (1994) An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin. J Cancer Res Clin Oncol 69:365–368CrossRefGoogle Scholar
  66. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, Laughlin EH, Alex JC (1995) Minimal access surgery for staging of malignant melanoma. Arch Surg 130:654–658PubMedGoogle Scholar
  67. Kroon BB, Nieweg OE (2000) Management of malignant melanoma. Arch Chir Gynaecol 89:242–250Google Scholar
  68. Krug B, Dietlein M, Groth W, Stutzer H, Psaras T, Gossmann A, Scheidhauer K, Schicha H, Lackner K (2000) Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol 41:446–452CrossRefPubMedGoogle Scholar
  69. Leong SPL, Steinmetz I, Habib FA, McMilian A, Gans JZ, Allen RE Jr, Morita ET, el-Kadi M, Epstein HD, Kashani-Sabet M, Sagebiel RW (1997) Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 132:666–672PubMedGoogle Scholar
  70. Lingam MK, Mackie RM, McKay AJ (1997) Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br Cancer 75:1505–1508Google Scholar
  71. Liw J, Zhang L, Zeng X (1996) Anorectal malignant melanoma. Report of 33 cases. Chung Hua Wai Ko Tsa Chih 34:665–667PubMedGoogle Scholar
  72. Macfarlane DJ, Sondak V, Johnson T, Wahl RL (1998) Prospective evaluation of 2-(18F)-2-deoxy-D-glucose positron emission tomography in staging of regional lymph-nodes in patients with cutaneous malignant melanoma. J Clin Oncol 16:1770–1776PubMedGoogle Scholar
  73. Martinez-Escribano JA, Navarro JL, Pinero A, Nicolas F, Frias JF, Sanchez Pedreno P, Parilla P (2001) Does injection distance of the radiocolloid modify lymphatic mapping in melanoma? Dermatol Surg 27:881–883CrossRefPubMedGoogle Scholar
  74. Mazzuca N, Bagnoni G, Solimeo C, Malvaldi F, Pratali R, Ceccarini M, Santini P, Morini V (2000) Sentinel node biopsy in clinical stage 1 melanoma: rationale for restaging and follow-up. Tumori 86(4):351–353PubMedGoogle Scholar
  75. McCarthy WH, Shaw HM, Milton GW (1985) Efficacy of elective lymph node dissection in 2347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 161:575–580PubMedGoogle Scholar
  76. McMasters KM (2001) The Sunbelt Melanoma Trial. Ann Surg Oncol 8(9):41S–43SPubMedGoogle Scholar
  77. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, Noyes RD, Viar V, Cerrito PB, Edwards MJ (2001) Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 8(3):192–197PubMedGoogle Scholar
  78. McMasters KM, Sober A, Kirkwood JM (2003) Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence resisted (author reply). Arch Dermatol 139(1):99–100PubMedGoogle Scholar
  79. Miliotes G, Albertini J, Berman C, Heller R, Messina J, Glass F, Cruse W, Rapaport D, Puleo C, Fenske N, Petsoglou C, Deconti R, Lyman G, Reintgen D (1996) The tumor biology of melanoma nodal metastases. Am Surg 62:81–88PubMedGoogle Scholar
  80. Morton DL (1984) Surgical treatment of malignant melanoma. Clin Oncol 3:517–529Google Scholar
  81. Morton DL (1997) Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 66:267–269CrossRefPubMedGoogle Scholar
  82. Morton DL, Wen DR, Cochran A (1992a) Management of early stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1:247–259Google Scholar
  83. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992b) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399PubMedGoogle Scholar
  84. Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A (1993) Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 11:1751–1756PubMedGoogle Scholar
  85. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE et al (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453–463CrossRefPubMedGoogle Scholar
  86. Mudun A, Murray DR, Herda SC, Eshima D, Shattuck LA, Vansant JP, Taylor AT, Alazraki NP (1996) Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection and effectiveness of the intraoperative gamma probe. Radiology 199:171–175PubMedGoogle Scholar
  87. Munz DL, Altmeyer P, Sessler MJ, Hor G (1982) Axillary lymph node groups — the center in lymphatic drainage from the truncal skin in man. Clinical significance for management of malignant melanoma. Lymphology 15:143–147PubMedGoogle Scholar
  88. Nakayama T, Taback B, Turner R, Morton DL, Hoon DS (2001) Molecular clonality of in transit melanoma metastasis. Am J Pathol 158:1371–1378PubMedGoogle Scholar
  89. Nathanson SD, Anaya P, Avery M, Hetzel FW, Sarantou T, Havstad S (1997) Sentinel lymph node metastasis in experimental melanoma: relationship among primary tumor size, lymphatic vessel diameter and 99mTc-labeled human serum albumin clearance. Ann Surg Oncol 4:161–168PubMedGoogle Scholar
  90. Nathanson SD, Anaya P, Karvelis KC, Eck L, Havstad S (1997) Sentinel lymph node uptake of two different technetium-labeled radiocolloids. Ann Surg Oncol 4:104PubMedGoogle Scholar
  91. Orfanos CE, Jung HG, Rassner G, Wolff HH, Garbe C (1994) Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanomas der Haut. Hautarzt 45:285CrossRefPubMedGoogle Scholar
  92. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H, Wolff K (1998) Adjuvant interferon alpha-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425–1429PubMedGoogle Scholar
  93. Peters J, Rompel R, Büttner P, Teichelmann K, Garbe C (1996) Elektive Lymphknotendissektion bei primärem malignen Melanom. Hautarzt 47:29–34CrossRefPubMedGoogle Scholar
  94. Pijpers R, Collet GJ, Meijer S, Hoekstra OS (1995) The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 22:1238–1241CrossRefPubMedGoogle Scholar
  95. Pijpers R, Borgstein PJ, Meijer S, Hoekstra OS, Huttum LH van, Teule GJ (1997) Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 21:788–792, discussion 793CrossRefPubMedGoogle Scholar
  96. Pijpers R, Meijer S, Hoekstra OS, Collet GJ, Comans EF, Boom RP, Diest PJ van, Teule GJ (1997) Impact of lymphoscintigraphy on sentinel node identification with technetium 99m-colloidal albumin in breast cancer. J Nucl Med 38:366–368PubMedGoogle Scholar
  97. Pizzocaro C, Rossini PL, Magri GC, Manca G, Caglioni C, Manganoni MA, Giubbini R (2000) Sentinel node biopsy in melanoma: the experience of Brescia Civic Hospital. Tumori 86(4):349–350PubMedGoogle Scholar
  98. Ramnath EM, Kamath D, Brobeil A, Stall A, Kamath VV, Cruse CV, Glass F, Messina J, Fenske N, Berman C, Ross ML, Cantor A, Cuthbertson D, Reintgen DS (1997) Lymphatic mapping for melanoma: long term result of regional nodal sampling with radioguided surgery. Cancer Control 4:483–490PubMedGoogle Scholar
  99. Reintgen DS (1996) Changing standards of surgical care for the melanoma patient. Ann Surg Oncol 3:327–328PubMedGoogle Scholar
  100. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220:759–767PubMedGoogle Scholar
  101. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, Schroer K, Heller R, Ross M, Lyman G (1996) The orderly progression of melanoma nodal metastases. Ann Surg Oncol 3:327–328PubMedGoogle Scholar
  102. Reintgen D, Balch DM, Kirkwood J, Ross M (1997) Recent advances in the care of the patient with malignant melanoma. Ann Surg 225:1–15CrossRefPubMedGoogle Scholar
  103. Retsas S, Henry K, Mohammed MQ, MacRae K (2002) Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 38(4):511–516CrossRefPubMedGoogle Scholar
  104. Rogers JM, Jung CW, Lewis G, Groman EV (1998) Use of USPIO-induced magnet susceptibility artifacts to identify sentinel lymph-nodes and lymphatic drainage patterns. I. Dependence of artifact size with subcutaneous combidex, dose in rats. Magn Reson Imaging 16:917–923CrossRefPubMedGoogle Scholar
  105. Ross MI, Reintgen D, Balch DM (1993) Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9:219–223PubMedGoogle Scholar
  106. Ross MI (1996) Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Semin Surg Oncol 12:394–401CrossRefPubMedGoogle Scholar
  107. Schneebaum S, Stadler J, Cohen M, Yaniv D, Baron J, Skornick Y (1998) Gamma probe-guided sentinel node biopsy — optimal timing for injection. Eur J Surg Oncol 24:515–519CrossRefPubMedGoogle Scholar
  108. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS (2000) A review of the literature for whole-body FDG-PET in the management of patients with melanoma. Q J Nucl Med 44:153–167PubMedGoogle Scholar
  109. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS (1998) Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 28(280):1410–1415CrossRefGoogle Scholar
  110. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gomagani P (1994) Axillary lymph node dissection for T1a breast carcinoma. Cancer 73:664–667Google Scholar
  111. Sugranes G, Vidal-Sicart S, Piulachs J, Bombuy E, Pons F, Castel T, Herranz R, Visa J (2001) Gamma-detecting probe used intraoperative to locate the sentinel lymph node status in patients with malignant melanoma. Eur J Surg 167(8):581–586CrossRefPubMedGoogle Scholar
  112. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS (2001) Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 61:5723–5726PubMedGoogle Scholar
  113. Temple CL, Scilley CG, Engel CJ, Shum DT, Lohmann RC, Mattar AG, Zabel PL (2000) Sentinel node biopsy in melanoma using technetium-99m rhenium colloid: the London experience. Ann Plast Surg 45(5):491–499PubMedGoogle Scholar
  114. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quinn MJ, Paramaesvara S, Crotty K, McCarthy SW, Uren RF, Howman-Giles R (1995) Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph-nodes. Melanoma Res 5:255–260PubMedGoogle Scholar
  115. Thompson JF, Niewind P, Uren RF, Bosch CM, Howman-Giles R, Vrouenraets BC (1997) Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res 7:500–506PubMedGoogle Scholar
  116. Thompson JF, Hunt JA, Culjak G, Kren RF, Howman-Giles R, Harman CR (2000) Popliteal lymph node metastasis from primary cutaneous melanoma. Eur J Surg Oncol 26:172–176CrossRefPubMedGoogle Scholar
  117. Thompson W, Gershenwald J, Lee J, Mansfield P, Balch C, Ross M (1996) Sentinel lymph node identification in melanoma patients using two techniques: dye vs. dye + radiolabelled colloid. Abstract presented to the Meeting of the Society of Surgical Oncology, Atlanta, 22 March 1996Google Scholar
  118. Tilgen W (1995) Malignant melanoma: current therapeutic concepts. Onkologie 18:534–547Google Scholar
  119. Tremblay F, Louffi A, Shibata H, Meteriossian S (2001) Sentinel lymph node biopsy for melanoma of the trunk and extremities: the McGill experience. Can J Surg 44(6):428–431PubMedGoogle Scholar
  120. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, Fi S, Coleman E, Seigler HF (2000) Positron emission tomography scanning in malignant melanoma. Cancer 89:1019–1025CrossRefPubMedGoogle Scholar
  121. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH (1993) Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 34:1435–1440PubMedGoogle Scholar
  122. Uren RF, Howman-Giles R, Thompson JF, Shaw HM, Quinn MJ, O'Brien CJ, McCarthy WH (1994) Lymphoscintigraphy to identify sentinel lymph-nodes in patients with melanoma. Melanoma Res 4:395–399PubMedGoogle Scholar
  123. Uren RF, Howman-Giles R, Thompson JF, Quinn MJ (1996) Direct lymphatic drainage from the skin of the forearm to a supraclavicular node. Clin Nucl Med 21:387–389CrossRefPubMedGoogle Scholar
  124. Uren RF, Howman-Giles R, Thompson JF, McCarthy WH (1998) Exclusive lymphatic drainage from a melanoma on the back to intraabdominal lymph-nodes. Clin Nucl Med 23:71–73CrossRefPubMedGoogle Scholar
  125. Uren RF, Howman-Giles R, Thompson JF, Shaw HM, Roberts JM, Bernard E, McCarthy WH (1999) High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph-nodes. Australes Radiol 43:148–152CrossRefGoogle Scholar
  126. Uren RF, Howman-Giles R, Thompson JF, McCarthy WH, Quinn MJ, Roberts JM, Shaw HM (2000) Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg 135(10):1168–1172CrossRefPubMedGoogle Scholar
  127. Veen H van der, Hoekstra OS, Paul MA, Cuesta MA, Meijer S (1994) Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 81:1769–1770PubMedGoogle Scholar
  128. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, Claudio F, Ikonopisiv RL, Javoorskj VV, Kirov S, Kulakowski A, Lacoub J, Lejeune F, Meche Z, Morabito A, Rode I, Sergeev S, von Slooten E, Szcygiel K, Trapeznikov NN (1977) Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 297:627–630PubMedGoogle Scholar
  129. Vidal-Sicart S, Pons F, Piulachs J, Castel T, Palou J, Herranz R (1998) Mid-arm sentinel lymph-nodes showing surprising drainage from a malignant melanoma in the forearm. Clin Nucl Med 23(5):273–274CrossRefPubMedGoogle Scholar
  130. Vorpahl U, Jager E, Schmidbauer U, Henneking K (1996) Value of inguinal lymph node excision in anorectal melanoma. Zentralbl Chir 121:483–486PubMedGoogle Scholar
  131. Wagner JD, Schauwecker D, Davidson D, Coleman JJ 3rd, Saxman S, Hutchins G, Love C, Hayes JT (1999) Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508–1515PubMedGoogle Scholar
  132. Wanebo HJ, Harpole D, Teates CD (1985) Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head, neck and trunk. Cancer 55:1403–1413PubMedGoogle Scholar
  133. Weinstock MA (1993) Cutaneous melanoma. J Am Acad Dermatol 28(4):666–668Google Scholar
  134. Weinstock MA (1993) Epidemiology and prognosis of anorectal melanoma. Gastroenterology 104:174–178PubMedGoogle Scholar
  135. Whooley BP, Shaw P, Astrow AB, Tofh IR, Wallack MK (1997) Long term survival after locally aggressive anorectal melanoma. Am Surg 64:245–251Google Scholar
  136. Winter H, Bellmann KP, Küchler I (1996) Prognoseverbesserung in der Melanomchirurgie — Ergebnisse zehn Jahre nach Einführung der Lymphabstromszintigraphie. In: Dümmer R, Pahizzon R, Burg G (eds) Operative und konservative Dermato-Onkologie. Blackwell, Berlin, pp 132–137Google Scholar
  137. Winter H, Küchler I, Aurisch R (1996) Prognoseverbesserung in der Melanomchirurgie durch lymphabstromgerechte Kontinuitätsdissection. Erfahrungen 10 Jahre nach Einführung der Lymphabstromszintigraphie. Acta Chir 31:282–290Google Scholar
  138. World Health Organization: Support in form of illustrative slides from Derm Pathol Fndn USA. WHO, Geneva. See also: Heenan et al (1974, 1996)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations